Product
DBV712
Aliases
DBV712 250 mcg, ViaskinTM Peanut
3 clinical trials
2 indications
Indication
AllergyIndication
Peanut AllergyClinical trial
A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy With DBV712 250 μg in 4-7-year-old Children With Peanut Allergy (VITESSE)Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Viaskin® Peanut (DBV712) Compassionate Use in Peanut-allergic Children Previously Enrolled in a DBV712 Clinical StudyStatus:
Clinical trial
EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic ChildrenStatus: , Estimated PCD: 2023-06-01